Obesity remains a major global health challenge with increasing prevalence rates despite decades of long-standing efforts focused on lifestyle interventions, pharmacotherapy, and surgery. The rapid development of highly effective incretin-based therapies has transformed obesity care by achieving clinically significant and substantial weight loss. Building on this success, an expanding therapeutic pipeline-including dual and triple agonists, amylin analogues, and other multimodal agents-targets complementary pathways and more closely aligns treatment with the biological complexity of obesity. Together, these advancements offer a promising future for long-term, sustainable obesity management and may help shift population-level trends. This review summarizes current evidence from published trials on the mechanisms, efficacy, and safety of approved and investigational medications, and highlights the potential impact of these therapies on the evolving landscape of obesity care.
Bassatne et al. (Thu,) studied this question.